Advances in Mouse Models of Lupus
DOI:
https://doi.org/10.54097/z699c962Keywords:
SLE, Mouse, Animal Model, Pristane, NZB, NZW, cGVHDAbstract
Systemic lupus erythematosus (SLE) is a typical autoimmune disease with complex clinical manifestations and involvement of organs and tissues of multiple systems throughout the body, but its pathogenesis is still unclear, therefore, the establishment of a suitable animal model of lupus is of great significance in exploring the etiology, pathogenesis and treatment of SLE. Constructing a lupus mouse model is a good tool for studying SLE. In this review, we will introduce the methods of establishing different kinds of lupus mouse models and their characteristics, and discuss the advantages and disadvantages of various models, with a view to providing researchers with references in the process of exploring the pathogenesis of lupus, and in the development of targeted interventions and therapeutic drugs.
Downloads
References
ZUCCHI D, ELEFANTE E, SCHILIRÒ D, et al. One year in review 2022: systemic lupus erythematosus[J/OL]. Clinical and Experimental Rheumatology, 2022, 40(1): 4-14.
BAGAVANT H, MICHROWSKA A, DESHMUKH U S. The NZB/W F1 mouse model for Sjögren’s syndrome: A historical perspective and lessons learned[J/OL]. Autoimmunity Reviews, 2020, 19(12): 102686.
YOUNES S T, SHOWMAKER K, JOHNSON A C, et al. Single cell RNA sequencing reveals ferritin as a key mediator of autoimmune pre-disposition in a mouse model of systemic lupus erythematosus[J/OL]. Scientific Reports, 2021, 11(1): 24245.
GILL R F, MATHIEU P A, LASH L H, et al. Naturally occurring autoimmune disease in (NZB X NZW) F1 mice is correlated with suppression of MZ B cell development due to aberrant B Cell Receptor (BCR) signaling, which is exacerbated by exposure to inorganic mercury[J/OL]. Toxicological Sciences: An Official Journal of the Society of Toxicology, 2023, 197(2): 211-221.
HALKOM A, WU H, LU Q. Contribution of mouse models in our understanding of lupus[J/OL]. International Reviews of Immunology, 2020, 39(4): 174-187.
CUNNINGHAM M A, RICHARD M L, WIRTH J R, et al. Novel mechanism for estrogen receptor alpha modulation of murine lupus[J/OL]. Journal of Autoimmunity, 2019, 97: 59-69.
CHU S Y, PONG E, BONZON C, et al. Inhibition of B cell activation following in vivo co-engagement of B cell antigen receptor and Fcγ receptor IIb in non-autoimmune-prone and SLE-prone mice[J/OL]. Journal of Translational Autoimmunity, 2021, 4: 100075.
WIRTH J R, MOLANO I, RUIZ P, et al. TLR7 Agonism Accelerates Disease and Causes a Fatal Myeloproliferative Disorder in NZM 2410 Lupus Mice[J/OL]. Frontiers in Immunology, 2019, 10: 3054.
FLORES R, ZHANG P, WU W, et al. Siglec genes confer resistance to systemic lupus erythematosus in humans and mice[J/OL]. Cellular & Molecular Immunology, 2019, 16(2): 154-164.
DAVIS M J, MARTIN R E, PINHEIRO G M, et al. Inbred SJL mice recapitulate human resistance to Cryptococcus infection due to differential immune activation[J/OL]. mBio, 2023, 14(5): e0212323.
DOU D R, ZHAO Y, BELK J A, et al. Xist ribonucleoproteins promote female sex-biased autoimmunity[J/OL]. Cell, 2024, 187 (3): 733-749.e16.
CHEN X C, WU D, WU H L, et al. Metformin improves renal injury of MRL/lpr lupus-prone mice via the AMPK/STAT3 pathway [J/OL]. Lupus Science & Medicine, 2022, 9(1): e000611.
CHEN K, DENG Y, SHANG S, et al. Complement factor B inhibitor LNP023 improves lupus nephritis in MRL/lpr mice[J/OL]. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 2022, 153: 113433.
NAMBA T, ICHII O, NAKAMURA T, et al. Compartmentalization of interleukin 36 subfamily according to inducible and constitutive expression in the kidneys of a murine autoimmune nephritis model[J/OL]. Cell and Tissue Research, 2021, 386(1): 59-77.
HAN X, XU T, DING C, et al. Neuronal NR4A1 deficiency drives complement-coordinated synaptic stripping by microglia in a mouse model of lupus[J/OL]. Signal Transduction and Targeted Therapy, 2022, 7(1): 50.
TOMALLA V, SCHMEISSER M J, WEINMANN-MENKE J. Mouse models, antibodies, and neuroimaging: Current knowledge and future perspectives in neuropsychiatric systemic lupus erythematosus (NPSLE)[J/OL]. Frontiers in Psychiatry, 2023, 14: 1078607.
ALMIZRAQ R J, FRIAS BOLIGAN K, LORIAMINI M, et al. (NZW × BXSB) F1 male mice: An unusual, severe and fatal mouse model of lupus erythematosus[J/OL]. Frontiers in Immunology, 2022, 13: 977698.
NAMBA T, ICHII O, NAKAMURA T, et al. Altered morpho-functional features of bones in autoimmune disease-prone BXSB/MpJ- Yaa mice[J/OL]. Experimental Biology and Medicine (Maywood, N.J.), 2019, 244(5): 333-343.
YUAN X, DAI B, YANG L, et al. Emodin ameliorates renal injury in BXSB mice by modulating TNF-α/ICAM-1[J/OL]. Bioscience Reports, 2020, 40(9): BSR20202551.
SAITOH S I, SAITOH Y M, KONTANI K, et al. ADP-ribosylation factor-like 8b is required for the development of mouse models of systemic lupus erythematosus[J/OL]. International Immunology, 2019, 31(4): 225-237.
HONG H, ALDURAIBI F, PONDER D, et al. Host Genetics But Not Commensal Microbiota Determines the Initial Development of Systemic Autoimmune Disease in BXD2 Mice [J/OL]. Arthritis & Rheumatology (Hoboken, N.J.), 2022, 74(4): 634-640.
CHEN J, LIAO S, ZHOU H, et al. Humanized Mouse Models of Systemic Lupus Erythematosus: Opportunities and Challenges[J/OL]. Frontiers in Immunology, 2021, 12: 816956.
MIAO N, WANG Z, WANG Q, et al. Oxidized mitochondrial DNA induces gasdermin D oligomerization in systemic lupus erythematosus[J/OL]. Nature Communications, 2023, 14(1): 872.
YANG F, HE Y, ZHAI Z, et al. Programmed Cell Death Pathways in the Pathogenesis of Systemic Lupus Erythematosus [J/OL]. Journal of Immunology Research, 2019, 2019: 3638562.
SOLHJOO M, GOYAL A, CHAUHAN K. Drug-Induced Lupus Erythematosus[M/OL]//StatPearls. Treasure Island (FL): StatPearls Publishing, 2024[2024-03-16].
RESÉNDIZ-MORA A, LANDA C, SÁNCHEZ-BARBOSA S, et al. Lupresan, a new drug that prevents or reverts the formation of nonbilayer phospholipid arrangements that trigger a murine lupus resembling human lupus[J/OL]. Biochemical and Biophysical Research Communications, 2019, 509(1): 275-280.
RESÉNDIZ-MORA A, WONG-BAEZA C, NEVÁREZ-LECHUGA I, et al. Interleukin 4 deficiency limits the development of a lupus-like disease in mice triggered by phospholipids in a non-bilayer arrangement[J/OL]. Scandinavian Journal of Immunology, 2021, 93(3): e13002.
ZHANG J, WANG X, WANG R, et al. Rapamycin Treatment Alleviates Chronic GVHD-Induced Lupus Nephritis in Mice by Recovering IL-2 Production and Regulatory T Cells While Inhibiting Effector T Cells Activation[J/OL]. Biomedicines, 2023, 11(3): 949.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
